Influence of glycemic control on the development of diabetic cardiovascular and kidney disease

Cardiology Clinics
Sandeep A Saha, Katherine R Tuttle

Abstract

Diabetes mellitus leads to the development of a host of micro- and macrovascular complications, which collectively lead to substantial morbidity and mortality. Among the microvascular complications of diabetes, diabetic kidney disease is the most common. Macrovascular complications from diabetes lead to a 2- to 4-fold increase in the incidence of cardiovascular disease and up to twice the mortality from cardiovascular causes as compared with nondiabetic individuals. This article discusses the various drug classes used to treat diabetes mellitus, and reviews the current clinical evidence linking glycemic control using these drug classes on diabetic kidney and cardiovascular disease.

References

Jan 1, 1986·Diabetologia·M NauckW Creutzfeldt
Jan 1, 1997·The American Journal of Medicine·M B Davidson, A L Peters
Jan 24, 1998·The New England Journal of Medicine·R I MisbinG A Fleming
Jun 18, 1999·Diabetes Care·M StangD Butler-Jones
Aug 24, 1999·Annals of Internal Medicine·R A DeFronzo
Feb 26, 2000·Journal of Medicinal Chemistry·T M WillsonB R Henke
May 12, 2001·European Journal of Pharmacology·R J LegtenbergP Smits
Jun 22, 2001·European Journal of Clinical Pharmacology·S SchumacherC Hasslacher
Oct 18, 2002·European Journal of Internal Medicine·Rita RachmaniMordchai Ravid
Nov 27, 2002·Journal of the American Dietetic Association·Paula TrumboUNKNOWN Food and Nutrition Board of the Institute of Medicine, The National Academies
Jan 29, 2003·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Enrique MoralesManuel Praga
Jan 31, 2003·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Feb 8, 2003·The Journal of Clinical Endocrinology and Metabolism·Tsung-Ming Lee, Tsai-Fwu Chou
Mar 1, 2003·Diabetes Care·Christoph Hasslacher, UNKNOWN Multinational Repaglinide Renal Study Group
Apr 10, 2003·JAMA : the Journal of the American Medical Association·Katherine EspositoDario Giugliano
Jul 24, 2003·JAMA : the Journal of the American Medical Association·Jean-Louis ChiassonUNKNOWN STOP-NIDDM Trial Research Group
Dec 8, 2004·The Journal of Clinical Endocrinology and Metabolism·G SchernthanerUNKNOWN Quartet [corrected] Study Group
Apr 12, 2005·Advances in Chronic Kidney Disease·Mark E Williams, Katherine R Tuttle
Mar 11, 2006·Diabetes Care·Sergio Muntoni
Apr 22, 2006·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Jean-Louis Chiasson
Jun 14, 2006·Retina·Edwin H RyanDavid F Williams
Aug 3, 2006·Kidney International·P A Sarafidis, G L Bakris
Nov 15, 2006·JAMA : the Journal of the American Medical Association·Theodore MazzoneSteven M Haffner
Feb 6, 2007·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·UNKNOWN KDOQI
Jul 12, 2007·JAMA : the Journal of the American Medical Association·Renee E AmoriAnastassios G Pittas
Aug 8, 2007·Annals of Internal Medicine·George A DiamondSanjay Kaul

❮ Previous
Next ❯

Citations

Aug 2, 2011·Journal of Diabetes Investigation·Daisuke KoyaMasakazu Haneda
Dec 30, 2011·American Journal of Physiology. Renal Physiology·Michael S SimonsonFaramarz Ismail-Beigi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.